MAIN CONTENT
A narrowly defined approval with broad significance
The FDA authorization is specific. Adults must have estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer carrying an ESR1 mutation detected with an authorized test. Their cancer must have recurred during or after endocrine-based adjuvant treatment, or progressed after at least one endocrine-based regimen in the metastatic setting. The approval covers giredestrant with everolimus; it does not make giredestrant monotherapy a broadly approved treatment.
ESR1 mutations can keep the estrogen receptor active even as conventional endocrine medicines try to shut down the signals that help tumors grow. Roche says such mutations are an important source of resistance in hormone receptor-positive metastatic disease. Molecular testing therefore has a practical purpose: it identifies a biological vulnerability rather than assuming that patients sharing a diagnosis will respond to the same drug.
Alongside the medicine, the agency authorized FoundationOne Liquid CDx as a companion diagnostic for identifying ESR1 mutations. The paired decisions illustrate how cancer treatment increasingly depends on the relationship between the tumor’s genetics, the therapies already tried and a patient’s broader clinical condition.















